Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

Blood (2024) 143 (3): 258–271.

https://doi.org/10.1182/blood.2022018905

Published: 2024

Includes: Supplemental data

Journal Articles

The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

Nanni Schmitt, Jana-Julia Siegler, Lena Wagner, Nicole Schulze, Alexandra Beck, Wolf-Karsten Hofmann, Torsten Haneke, Uwe Reusch, José Medina-Echeverz, Jan Endell, Thorsten Ross, Christian Merz, Daniel Nowak

Blood (2022) 140 (Supplement 1): 8815–8816.

https://doi.org/10.1182/blood-2022-169729

Published: 2022

Journal Articles

The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models

Blood (2021) 138 (Supplement 1): 2412.

https://doi.org/10.1182/blood-2021-145649

Published: 2021

Journal Articles

The Combination of Tafasitamab and Rituximab Increases Cytotoxicity Against Lymphoma Cells I n Vitro

Maria Patra, Christian Augsberger, Carmen Ginzel, Andrea Polzer, Karin Landgraf, Dominik Bartel, Daniel Ness, Stefan Steidl, Christina Heitmüller, Juergen Schanzer, Jan Endell

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-140381

Published: 2020

Journal Articles

Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells after Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data

Rainer Boxhammer, Frank Striebel, Roland Baumgartner, Jan Endell

Blood (2019) 134 (Supplement_1): 5061.

https://doi.org/10.1182/blood-2019-128613

Published: 2019

Journal Articles

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Pedro Horna, MD, Grzegorz Nowakowski, MD, Jan Endell, Rainer Boxhammer

Blood (2019) 134 (Supplement_1): 5345.

https://doi.org/10.1182/blood-2019-129600

Published: 2019

Journal Articles

Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

Paulina Horvei, MD, Reona Sakemura, MD PhD, Michelle J. Cox, Michael W. Ruff, MD, Mehrdad Hefazi, MD, Erin E. Tapper, Kendall J. Schick, Claudia Manriquez Roman, Charles J. Kuhlmann, Juergen Schanzer, Jan Endell, Grzegorz Nowakowski, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 2859.

https://doi.org/10.1182/blood-2019-130506

Published: 2019

Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell

Blood (2019) 134 (Supplement_1): 3801.

https://doi.org/10.1182/blood-2019-128511

Published: 2019

Journal Articles

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Dimitrios Mougiakakos, MD, Simon Voelkl, PhD, Christian Bach, Andrej Stoll, Katrin Bitterer, Fabian Beier, MD, Jan Endell, Rainer Boxhammer, Jörg Thomas Bittenbring, MD, Andreas Mackensen, MD, Heiko Bruns, PhD

Blood (2019) 134 (Supplement_1): 4064.

https://doi.org/10.1182/blood-2019-124886

Published: 2019

Journal Articles

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Marc S. Raab, MD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, Hermann Einsele, MD, Monika Engelhardt, MD PhD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Röllig, MD, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Jan Endell, PhD, Rainer Boxhammer, PhD, Christian Peschel, MD

Blood (2016) 128 (22): 1152.

https://doi.org/10.1182/blood.V128.22.1152.1152

Published: 2016

Journal Articles

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Gianluca Gaidano, MD PhD, Andre Goy, MD, Mariano Provencio, MD PhD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD PhD, Kami J. Maddocks, MD, Christian Buske, Sumeet Ambarkhane, MD, Mark Winderlich, PhD, Maren Dirnberger-Hertweck, PhD, Jan Endell, PhD, Kristie A Blum, MD

Blood (2016) 128 (22): 623.

https://doi.org/10.1182/blood.V128.22.623.623

Published: 2016

Journal Articles

MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds

Rainer Boxhammer, Johannes Weirather, PhD, Stefan Steidl, PhD, Jan Endell, PhD

Blood (2015) 126 (23): 3015.

https://doi.org/10.1182/blood.V126.23.3015.3015

Published: 2015

Journal Articles

Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide

Jan Endell, Rainer Boxhammer, Stefan Steidl

Blood (2014) 124 (21): 5712.

https://doi.org/10.1182/blood.V124.21.5712.5712

Published: 2014

Journal Articles

The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo

Jan Endell, Rainer Boxhammer, Cornelia Wurzenberger, Daniel Ness, Stefan Steidl

Blood (2012) 120 (21): 4018.

https://doi.org/10.1182/blood.V120.21.4018.4018

Published: 2012

NARROW

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models

The Combination of Tafasitamab and Rituximab Increases Cytotoxicity Against Lymphoma Cells I n Vitro

Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells after Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds

Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide

The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only